Indications
Peripheral vascular disease
This is indicated in-
Peripheral arterial occlusive disease (PAOD) of arteriosclerotic or diabetic origin (e.g. with intermittent claudication and rest pain)
Trophic lesions (e.g. leg ulcers and gangrene)
Cerebral vascular diseases
Circulatory disturbances of the eye in conjunction with degenerative vascular disorders.
Dosage And Administration
In principle, dosage is based on the type and severity of the circulatory disorders and on how the individual patient tolerates the drug. Usual dosage is 400 mg pentoxifylline 2 to 3 times daily. Tablets are to be swallowed whole during or shortly after a meal with sufficient amounts of liquid (approx. ½ glass).
Side Effects
These adverse reactions have been reported in clinical trials or post-marketing-
Investigations: Transaminases increased (Transaminase elevation), Blood pressure decreased (Fall in blood pressure)
Cardiac disorders: Arrhythmia (Cardiac arrhythmia), Tachycardia, Angina Pectoris
Blood and lymphatic system disorders: Thrombocytopenia (Thrombopenia), Leucopenia/neutropenia
Nervous system disorders: Dizziness, headache, meningitis aseptic (Aseptic meningitis)
Gastrointestinal disorders: Gastrointestinal disorder (Gastrointestinal complaints), Epigastric discomfort (Gastric pressure), Abdominal distension (Fullness), Nausea, Vomiting, Diarrhoea, Constipation, Hypersalivation
Skin and subcutaneous tissue disorders: Pruritus, Erythema (Reddening of the skin), Urticaria, Rash
Vascular disorders: Hot fush (Flushes), Haemorrhage (Bleedings)
Immune system disorders: Anaphylactic reaction, Anaphylactoid reaction, Angioedema (Angioneurotic edema), Bronchospasm, Anaphylactic shock (shock)
Hepatobiliary disorders: Cholestasis (Intrahepatic cholestasis)
Psychiatric disorders: Agitation, Sleep disorder (Sleep disturbances)
Precautions And Warnings
At the first signs of an anaphylactic/anaphylactoid reaction, Pentoxifylline must be discontinued or the infusion be halted immediately, and a physician must be informed. Particularly careful monitoring is required:
in patients with severe cardiac arrhythmias
in patients with myocardial infarction
in hypotensive patients
in patients with impaired renal function (creatinine clearance below 30 ml/min)
in patients with severely impaired liver function
in patients with increased bleeding
in patients treated concomitantly with pentoxifylline and anti-vitamin K or platelet aggregation inhibitors
in patients treated concomitantly with pentoxifylline and antidiabetic agents
in patients treated concomitantly with pentoxifylline and ciprofoxacin
in patients treated concomitantly with pentoxifylline and theophylline
Pregnancy And Lactation
Insufficient experience has been gained concerning use in pregnancy. Therefore, it is recommended that Pentoxifylline is not used during pregnancy. Pentoxifylline passes into breast milk in minute quantities. Because insufficient experience has been gained, the physician must carefully weigh the possible risks and benefits before administering Pentoxifylline in breast-feeding women.